Page 4 - Novartis Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Dr Reddy s and Novartis sign distribution agreement for anti-diabetes products

The partnership is a strategic move for DRL as it aims to expand into the cardio and diabetes therapeutic areas.

United kingdomNovartis pharmaReddy laboratoriesLaboratorie russianGalvus metAnnual totalPharmaceutical technology

Dr Reddy s Laboratories LLC, Russia Enters into Distribution Agreement with Novartis Pharma LLC

Dr Reddy s Laboratories LLC, Russia Enters into Distribution Agreement with Novartis Pharma LLC
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Reddy laboratoriesNovartis pharmaGalvus metAnnual total

Niterra : Notice of Convocation Annual General Meeting 2024

Niterra : Notice of Convocation Annual General Meeting 2024
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Higashi kuJapan generalToru matsuiNovartis pharmaTakayoshi mimuraTakeshi kawaiShinichi odoChiharu takakuraHisanori makayaMiwako doiCompany information serviceSupervisory committeeOffice buildingNomura research institute ltdNiterra north america incPromotion division

Revolution Medicines (NASDAQ:RVMD) & Precision BioSciences (NASDAQ:DTIL) Head-To-Head Analysis

Revolution Medicines (NASDAQ:RVMD) & Precision BioSciences (NASDAQ:DTIL) Head-To-Head Analysis
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

North carolinaUnited statesRedwood cityDuke universityEli lillyPrecision biosciences incRevolution medicines incCaribou biosciences incTg cell therapy incSecure incPrecision biosciencesGet free reportRevolution medicinesGiven precision bioscienceRevolution medicineCaribou biosciences

Novartis Meets Offer Conditions To Buy MorphoSys In EUR 68/shr Cash Deal

Novartis Pharma AG, affiliated to Swiss drug major Novartis AG (NVS), announced Thursday that it has met all tender offer conditions to acquire MorphoSys AG (MOR) for EUR 68 per share in cash.

Novartis bidcoNovartis pharma